

# Table of contents

Acknowledgements	11
List of tables and figures	14
Chapter 1: Introduction: objectives of the study	15
Chapter 2: Methodological design	19
1 Introduction	19
2 Sample countries	19
3 National key contacts	20
4 Malta: distant data collection	21
5 Sample prisons	25
6 Selection of NGO's	30
7 Field visits	36
7.1 Structure of field visits	37
7.2 Qualitative techniques and representativity	39
7.2 Interview settings	40
7.4 Linguistic problems: the use of interpreters	40
7.5 Ethics	41
7.6 Methodological issues arising from the fieldwork	41
Chapter 3:	
Cocaine and Amphetamine Type Stimulants in Europe	43
1 Introduction	43
2 Prevalence, patterns and trends in the general population	45
2.1 Adult population	45
2.1.1 Cocaine	45
2.1.2 Amphetamine Type Stimulants	48
2.1.2.1 Ecstasy	48

2.1.2.2	Amphetamines	51
2.2	School youth	53
2.2.1	Cocaine	53
2.2.2	Amphetamine Type Stimulants	54
3	Cocaine and Amphetamine Type Stimulants-treatment	55
3.1	Treatment demand data	55
3.1.1	Cocaine treatment demand	55
3.1.2	Amphetamine	58
3.1.3	Ecstasy	60
3.2	Client profiles	61
3.2.1	Cocaine users	61
3.2.2	Amphetamine Type Stimulant users	63
3.3	Treatment services	63
4	Drug related deaths	65
4.1	Cocaine	65
4.2	Amphetamine Type Stimulants	68
5	Reducing drug-related harm	69
5.1	Cocaine	69
5.1.1	General trends in Europe	69
5.1.2	Needle exchange programs	69
5.1.3	Substitution treatment	70
5.1.4	Prevention	70
5.2	Amphetamine Type Stimulants	70
6	Markets, seizures, prices and purity	71
6.1	Cocaine	71
6.2	Amphetamine Type Stimulants	74
6.2.1	Amphetamines	74
6.2.2	Ecstasy	77
7	Conclusion	80

Chapter 4: Cocaine and ATS use(rs) in European prisons	83
1 Introduction	83
2 Prevalence of cocaine and ATS use in European prisons	84
2.1 Indirect indicators of drug use	84
2.2 Underreporting	85
2.3 Perceived trends in cocaine and ATS use in prison	87
2.4 Poly drug use	92
2.5 Methods of cocaine and ATS use	93
3 Factors influencing cocaine and Amphetamine Type Stimulant use in prison	95
3.1 Pre-prison drug use	95
3.2 Availability	96
3.3 Price of cocaine in prison	100
3.4 Advantages of cocaine and Amphetamine Type Stimulant use in prison	102
3.5 Disadvantages of cocaine and Amphetamine Type Stimulant use in prison	103
3.6 Availability of alternatives for drugs	104
3.7 Change in patterns	104
4 Profiles of cocaine and Amphetamine Type Stimulant users in prison	105
4.1 Different groups of users	105
4.2 Younger users?	106
4.3 More women?	106
4.4 Different socio-economic backgrounds	107
4.5 Different psychological traits?	108
4.6 Less problem recognition	109
5 Reported problems and risks related to cocaine and ATS use in prison	109
5.1 Aggression and violence	110
5.2 Psychological symptoms	111
5.3 Insomnia and other physical problems	112
5.4 Hyperactivity and ADHD	113
5.5 Automutilation and suicidal tendencies	114
5.6 Lack of problem awareness	114
5.7 Difficult to recognise	115

5.8	No treatment expertise	115
5.9	Sexual risk behaviour	116
6	Specific needs of cocaine and ATS users in prison	116
6.1	No specific needs?	117
6.2	Specific product information and harm reduction information	119
6.3	(Guidelines for) management of acute intoxication	120
6.4	(Guidelines for) management of withdrawal from stimulants	120
6.5	Pharmacological treatment	121
6.6	Improve potential for diagnosis of personality and psychiatric disorders	122
6.7	Non-pharmacological treatment	123
6.8	Alternatives to drug use in prison	124
7	Conclusions	124
Chapter 5: Problems and practice in prison systems		131
1	Introduction	131
2	Targeted services for stimulant users in European prisons	131
3	General services for stimulant users in European prisons	135
3.1	Prevention and harm reduction information	135
3.2	Condoms	138
3.3	Bleach	139
3.4	Needle exchange	141
3.5	Medical treatment	142
3.5.1	Substitution treatment	142
3.5.2	Detoxification	144
3.6	Psychosocial treatment	145
3.7	Differentiation inside prisons	147
4	Barriers to implementation of prison health care strategies	149
4.1	Evidence-based policies	149
4.2	National prison drug strategies: focus on supply reduction	150
4.3	Budget constraints	153
4.4	Over-incarceration of drug users	154
4.5	Attitude of contempt to drug users	155
4.6	Confidentiality	156
4.7	Prison health care: whose responsibility?	158
4.8	Security staff: qualifications and training	158

4.9	Health care staff: qualifications and training	160
4.10	Multidisciplinary working	161
4.11	Prisons and outside service providers (NGOs)	163
4.12	Overcrowding	166
4.13	Foreign prisoners	167
4.14	Staff shortage	169
4.15	Autonomy from central administration	172
5	Conclusions	172

## Chapter 6: Conclusion and Recommendations 175

1	Introduction	175
2	Cocaine and Amphetamine Type Stimulants in the community	176
3	Cocaine and Amphetamine Type Stimulants in prison	177
4	Problems and practice in prison systems	179
5	Recommendations regarding legislative and policy reform	182
6	Recommendations regarding prison policy reform	183
7	Recommendation regarding cocaine and Amphetamine Type Stimulants-related interventions	185

## References 189

Appendix 1 – Ethical and methodological guidelines	201
Appendix 2 – Focus group prisoners: topic list	205
Appendix 3 – Interview topic lists for professionals	207